EDGAR Filing Documents for 0000897069-02-000485

Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]:

SEC Accession No. 0000897069-02-000485

Filing Date

2002-06-27

Accepted

2002-06-27 15:29:43

Documents

Period of Report

2001-12-31

Document Format Files

Seq	Description	Document	Type	Size
1	FORM 20-F	slp315.txt	20-F	292496
3	RESEARCH AND LICENSE AGREEMENT AMENDMENT	slp315a.txt	EX-4.(J)	6522
	Complete submission text file	0000897069-02-000485.txt		300662

Mailing Address 9900 CAVENDISH BLVD., SUITE 306 ST. LAURENT QUEBEC CANADA A8 H4M 2V2

Business Address 9900 CAVENDISH BLVD., SUITE 306 ST. LAURENT QUEBEC CANADA A8 H4M 2V2 514-332-32

NYMOX PHARMACEUTICAL CORP (Filer) CIK: 0001018735 (see all company filings)

Fiscal Year End: 1231
Type: 20-F | Act: 34 | File No.: 001-12033 | Film No.: 02689084
SIC: 2835 In Vitro & In Vivo Diagnostic Substances